William Blair Weighs in on Billiontoone Q3 Earnings

Billiontoone, Inc. (NASDAQ:BLLN) – Stock analysts at William Blair issued their Q3 2025 earnings per share estimates for Billiontoone in a research note issued to investors on Monday, December 1st. William Blair analyst A. Brackmann expects that the company will post earnings per share of $0.14 for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Billiontoone’s Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.04) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.51 EPS and FY2028 earnings at $1.42 EPS.

BLLN has been the subject of a number of other research reports. JPMorgan Chase & Co. initiated coverage on shares of Billiontoone in a research note on Monday. They set an “overweight” rating and a $150.00 price objective for the company. BTIG Research initiated coverage on shares of Billiontoone in a research report on Monday. They set a “buy” rating and a $160.00 price target for the company. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a report on Saturday, November 15th. Jefferies Financial Group started coverage on Billiontoone in a report on Monday. They set a “hold” rating and a $117.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Billiontoone in a research report on Monday. They issued a “buy” rating and a $145.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

Billiontoone Trading Up 1.7%

NASDAQ BLLN opened at $114.92 on Wednesday. Billiontoone has a twelve month low of $88.00 and a twelve month high of $138.70.

Billiontoone Company Profile

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.